Why 2017 Was a Year to Forget for Core Laboratories N.V.
By most measures, oil-field services specialist Core Labs (NYSE: CLB) had an unimpressive 2017 campaign. Outside of a 2% dividend yield, the company didn't return much value to shareholders. In fact, shares are down 15% year to date. That's largely because a sharp recovery promised by management failed to materialize. Wall Street punished the stock for overpromising and underdelivering, which is why shareholders will be happy to forget 2017.
The good news is that the disappointing results weren't all that bad and the company is still running a healthy and profitable business thanks to its unique business model. The better news is that global energy prices are heading in the right direction to allow Core Labs to begin delivering on a long-awaited recovery -- albeit one year later than originally promised.
Image source: Getty Images.
Source: Fool.com
Core Laboratories Inc. Aktie
Leichtes Sell-Übergewicht bei Core Laboratories Inc. mit 3 Sell- gegenüber 0 Buy-Einschätzungen.
Ein negatives, wenn auch nicht starkes, Potenzial für Core Laboratories Inc. mit einem Kursziel von 14 € im Vergleich zu 15.0 €.
